Innovation in Medical Nutrition. Hanno Cappon

Transcription

1 Innovation in Medical Nutrition Hanno Cappon

2 Innovation is at the core of our Advanced Medical Nutrition mission To Lead the Use of Advanced Medical Nutrition in Disease Management Nutritional Intervention that improves clinical outcomes Become an integral part of disease treatment for Health Care Professionals

3 Our product categories cover a range of ages and diseases areas Medical Nutrition Nutrition for people who cannot eat or lack specific nutrients Fortimel Independence Nutrison Recovery Nutrini Faltering Growth Disease Targeted Nutrition Nutrition to alleviate disease symptoms or delay the progression of disease Neocate Allergy Relief Metabolic Control Diabetes Oncology COPD Alzheimer s

4 Strong science and medical credibility are the foundation Medical Marketing Sales Skills KOL Support Strong Science Medical Credibility Brand Awareness Messages for Sales Force Relationship Building Targeting Value Proposition Regulatory Management Screening Reimbursement Medical & KOL Credibility

5 X 000 (euro) Innovations and product upgrades contribute significantly to today s growth % % 22% 27% 34% Existing products Innovations/Upgrades

6 New Innovation remains an important driver of our growth and success Line Extensions Improvements Products New Benefits Breakthroughs Markets Existing 1. Accelerate growth in General and Pediatric Medical Nutrition through evidence, new benefits and compliance 2. Geographic expansion through affordable solutions 3. Strengthen growth in Disease-Targeted Nutrition through new evidence 4. New growth through breakthrough Therapeutic Nutrition

7 We serve a special consumer A substantial part of Frail and Elderly are malnourished: - 10% of over 65 year-olds in general - 50% of patients over 60 years old in hospitals - 60% of Nursing Home patients We develop products aimed at improving patient compliance

8 Improved compliance leads to increased nutritional intake Fortisip Compact: Less Volume, More Nutrition

9 Mastering technological solutions to create competitive benefits -40% Standard Fortisip 200ml Compressed Volume Fortisip 125ml Normal protein Fortisip Compact 125ml Specific protein fraction High viscosity Lower viscosity

10 We have developed a unique pediatric Faltering Growth portfolio Infatrini Nutritionally complete, high energy formula for children <1 yr With whey protein, prebiotics and ω-3 LCPs NutriniDrink Nutritionally complete, high energy drink for children > 1 yr Also in affordable powder Nutrini Tube Feeds Whey dominant protein to improve GI tolerance ω-3 LCPs to improve mental development MultiFibre-6 to improve bowel function Nutrini Peptisorb Hydrolyzed protein for improved digestion and absorption Nutrini LE MF Low energy, multi fiber formula for immobile, neurologically impaired children

11 X 000 (euro) Innovative pediatric nutrition portfolio drives sales growth 20,000 18,000 16,000 Nutrini Powder 2009 Q1 Upgrade Infatrini 500 ml 2009 Q1 Upgrade 14,000 12,000 10,000 8,000 6,000 4,000 2,000 Nutrini Pepti 2007 Q3 Innovation Fortini / Nutrinidrink 2007 Q1 Upgrade Nutrini LE MF 2005 Innovation Infatrini / Prebiotics 2005 Innovation Nutrini/Tentrini Upgrade 2009 Q1 Upgrade Existing sales 0 Q1/07 Q2/07 Q3/07 Q4/07 Q1/08 Q2/08 Q3/08 Q4/08 Q1/09 Q2/09 Q3/09

12 Our Disease-Targeted Nutrition promise Alleviate disease symptoms Reduce risk of complications COPD Epilepsy Enhance recovery Diabetes Dysphagia Retard disease progression Oncology Improve drug treatment effectiveness Alzheimer s

13 Nutrients target multi-factorial physiological systems Focused large effect on single target Small effects on multiple targets Pharma Nutrition Adapted from De Vos et al., 2006 Current opinion in biotechnology, 17:1-9

14 Synergistic combination of nutrients to stimulate brain membrane synthesis The Kennedy pathway for biosynthesis neuronal membrane UMP Phospholipids Choline * *** 60 Uridine Phosphocholine CDP-choline PUFA s Contr UMP DHA UMP +DHA Co-factors: B-vitamins Antioxidants DAG Phosphatidylcholine New neuronal membrane Prof Richard Wurtman MIT, Cambridge, USA * Fortasyn Connect = patented combination of nutrients

15 Delayed verbal memory WMS-r Clinical evidence: Souvenaid improves memory in mild Alzheimer s Disease Significant* (p=0.026) change from baseline in mild AD after 12 weeks Significant* (p=0.011) change from baseline in very mild (MMSE>23) AD 2 2 1,5 1, ,5 0,5 0 Souvenaid 0 Souvenaid -0,5-0,5-1 Control -1 Control Prof Scheltens VU Medical Centre, NL

16 HIV Clinical Trial Results Reduced CD4 + T cell decline and immune activation by NR100157, a specific multi-targeted nutritional intervention; a one year multicenter randomized trial in HIV-1 positive adults not on antiretroviral therapy (BITE) J. Lange 1, B. Gazzard 2, R. S. Diaz 3, A. Gori 4, B. van t Land 7, J. Raijmakers 5, A. Vriesema 5, D. Kotler 6, M. Clerici 4, J. Garssen 7, P. Cahn 8, and the BITE Study Group.

17 HIV infection affects multiple physiological targets HIV infection = immune disorder Modulates several physiological targets Nutritional Gut Immune Decreased glutathione levels Micronutrient deficiencies Increased gut permeability Disturbed gut microbiota Deteriorated immune function Hyper immune activation

18 Objective of our HIV clinical trial CD4 + (cells /µl blood) 1500 NR product 1000 Immunity 14 cells 500 Gut health nutrition 52 weeks

19 Change in CD4 + cell count HIV clinical trial result: Reduction of CD4+ T- cell decline Difference of 40 cells (p=0.030) cells Active cells Control Weeks An extremely clinically relevant difference which no drug has yet been able to demonstrate

20 To lead the use of Advanced Medical Nutrition in disease management